Результаты поиска

Navigating through novelties concerning mCRC treatment-the role of immunotherapy, chemotherapy, and targeted therapy in mCRC.

Over the course of nearly six decades since the inception of initial trials involving 5-FU in the treatment of mCRC (metastatic colorectal cancer), our progressive comprehension of the pathophysiology, genetics, and surgical techniques related to mCRC has paved the way for the introduction of novel therapeutic modalities. These advancements not only have augmented the overall survival but have also positively impacted the quality of life (QoL) for affected individuals. Despite the remarkable progress made in the last two decades in the development of chemotherapy, immunotherapy, and target the

Совпадение в полном тексте источника
… Irinotecan + Cetuximab (4.2 vs. 2 months) PANAMA | II | RAS WT mCRC | 248 | Panitumumab, folinic acid, fluorouracil | PFS | FU/FA + panitumumab vs. … In the PANAMA trial, panitumumab in combination with folinic acid and fluorouracil was confronted with fluorouracil and folinic acid alone in patients with RAS wild-type CRC. …

Microorganisms Associated with the Marine Sponge Scopalina hapalia: A Reservoir of Bioactive Molecules to Slow Down the Aging Process.

Aging research aims at developing therapies that delay normal aging processes and some related pathologies. Recently, many compounds and extracts from natural products have been shown to slow aging and/or extend lifespan. Marine sponges and their associated microorganisms have been found to produce a wide variety of bioactive secondary metabolites; however, those from the Southwest of the Indian Ocean are much less studied, especially regarding anti-aging activities. In this study, the microbial diversity of the marine sponge Scopalina hapalia was investigated by metagenomic analysis. Twenty-s

Совпадение в полном тексте источника
… This low number of fungal isolates is consistent with a previous study on the cultivable fungi from Panama, where three fungal strains were recovered from three different specimens of Scopalina [ 86 ]. … Phylogenetic Diversity of Sponge-Associated Fungi from the Caribbean and the Pacific of Panama and Their In Vitro Effect on Angiotensin and Endothelin Receptors. Mar. Biotechnol. 2015;17:533–564. doi: 10.1007/s10126-015-9634-z. 87. …

Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review.

The response to medications in children differs not only in comparison to adults but also between children of the different age groups and according to the disease. This is true for anti-infectives that are widely prescribed in children with malignancy. In the absence of pharmacokinetic/pharmacodynamic paediatric studies, dosage is frequently based on protocols adapted to adults. After a short presentation of the drugs, we reviewed the population pharmacokinetic studies available for glycopeptides (vancomycin and teicoplanin, n = 5) and antifungals (voriconazole, posaconazole, and amphotericin

Совпадение в полном тексте источника
… | Voriconazole | Posaconazole Author | Walsh 2004 Walsh et al. (2004) | Karlson 2009 Karlsson et al. (2009) | Muto 2015 Muto et al. (2015) | Gastine 2017 Gastine et al. (2017) | Boonsathorn Boonsathorn et al. (2019) Study location | United Kingdom/United States/Costa rica/Panama | Europe | Japan | …

Integrating Palliative Care into Oncology Care Worldwide: The Right Care in the Right Place at the Right Time.

Opinion statementWhile the benefits of early palliative care are indisputable, most of the current evidence has emerged from resource-rich settings in urban areas of high-income countries, with an emphasis on solid tumors in outpatient settings; this model of palliative care integration is not currently scalable internationally. A shortage of specialist palliative care clinicians means that in order to meet the needs of all patients who require support at any point along their advanced cancer trajectory, palliative care must also be provided by family physicians and oncology clinicians who req

Совпадение в полном тексте источника
… Finally, Panama represents a good example of a low- and middle-income country where the successful development of a sustainable national palliative care program has been possible [ 15 ]. …

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.

BackgroundC.E.R.A. (Continuous Erythropoietin Receptor Activator) is an innovative agent with unique erythropoietin receptor activity and prolonged half-life. This study evaluated C.E.R.A. once weekly (QW) or once every 3 weeks (Q3W) in patients with anemia and advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.MethodsIn this Phase II, randomized, open-label, multicenter, dose-finding study, patients (n = 218) with Stage IIIB or IV NSCLC and hemoglobin (Hb) or= 2 g/dL or achievement of Hb >or= 12 g/dL with no blood transfusion in the previous 28 days determined in two consecuti

Совпадение в полном тексте источника
… In addition to the authors of the present paper, the following investigators participated in the study: Mark Adler (USA), Bipinkumar Amin (USA), Juan Carlos Alcedo (Panama), Donald Berdeaux (USA), Leon Bosquee (Belgium), Linda Bosserman (USA), Peter Briggs (Australia), German Calderillo (Mexico), Felipe …

Global perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations.

BACKGROUND AND OBJECTIVES: Lupus nephritis (LN) remains a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). Although recent years have witnessed the approval of several targeted therapies, achieving long-term, drug-free remission remains challenging. This commentary evaluates the global landscape of interventional LN clinical trials from 2001 to 2026 to identify emerging trends and strategic gaps in drug development. METHODS: We analyzed 200 interventional pharmacological trials retrieved from three major global registries: ClinicalTrials.gov, Chinadrugtrials.org

Совпадение в полном тексте источника
… Hungary, Italy, Mexico, Peru, Poland, Russia, Serbia, South Korea, Spain, Taiwan (China), United Kingdom | III+/- V, IV +/- V NCT02550652 (Completed) | Phase II | 2015 | Obinutuzumab+MMF/Mycophenolic Acid (MPA) | United States, Argentina, Brazil, Colombia, Costa Rica, France, Israel, Italy, Mexico, Panama …

A multicountry ecological study of cancer incidence rates in 2008 with respect to various risk-modifying factors.

Observational and ecological studies are generally used to determine the presence of effect of cancer risk-modifying factors. Researchers generally agree that environmental factors such as smoking, alcohol consumption, poor diet, lack of physical activity, and low serum 25-hdyroxyvitamin D levels are important cancer risk factors. This ecological study used age-adjusted incidence rates for 21 cancers for 157 countries (87 with high-quality data) in 2008 with respect to dietary supply and other factors, including per capita gross domestic product, life expectancy, lung cancer incidence rate (an

Совпадение в полном тексте источника
… Finland, France, Georgia, Germany, Greece, Guatemala, Guyana, Hungary, Iceland, Iran, Ireland, Israel, Italy, Jamaica, Japan, Kazakhstan, Korea (Republic), Kuwait, Kyrgyzstan, Latvia, Lithuania, Luxembourg, Macedonia, Malaysia, Mauritius, Mexico, Mongolia, Netherlands, New Zealand, Nicaragua, Norway, Panama …

A rare presentation of langerhans cell histiocytosis tonsil infiltration: review of the literature: atypical presentation of langerhans cell histiocytosis.

MedImmune Vaccines (formerly Aviron) has developed a cold-adapted live influenza virus vaccine [FluMist] that can be administered by nasal s … available in the US. For the 2003-2004 season, FluMist will contain A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) (A/Moscow/10/99-like) and B/Hong Kong/330/2001. Aviron was acquired by MedImmune on 15 January 2002. Aviron is now a wholly-owned subsidiary of MedImmune and is called MedImmune Vaccines. Aviron acquired FluMist in March 1995 through …

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

BACKGROUND: How long one lives, how many years of life are spent in good and poor health, and how the population's state of health and leading causes of disability change over time all have implications for policy, planning, and provision of services. We comparatively assessed the patterns and trends of healthy life expectancy (HALE), which quantifies the number of years of life expected to be lived in good health, and the complementary measure of disability-adjusted life-years (DALYs), a composite measure of disease burden capturing both premature mortality and prevalence and severity of ill

Совпадение в полном тексте источника
… 6·0) | 78·5 (78·2–78·8) | 68·6 (68·2–68·9) | 72·6 (72·3–72·9) | 64·7 (62·1–67·0) | 68·2 (65·3–70·7) | 61·0 (58·9–62·9) | 64·2 (61·8–66·3) Nicaragua | 74·1 (73·2–74·9) | 80·6 (79·4–82·0) | 69·7 (68·6–70·7) | 76·9 (75·3–78·4) | 63·5 (60·5–66·2) | 69·8 (66·6–72·7) | 61·2 (58·6–63·4) | 67·8 (65·1–70·5) Panama … 17·6) | 19·1 (18·9–19·2) | 16·0 (16·0–16·0) | 17·3 (17·1–17·4) | 13·2 (12·0–14·2) | 14·3 (13·0–15·4) | 12·3 (11·2–13·2) | 13·1 (12·0–14·2) Nicaragua | 19·1 (18·6–19·6) | 20·6 (19·7–21·5) | 18·0 (17·4–18·6) | 19·9 (18·9–20·7) | 14·2 (12·8–15·4) | 15·4 (13·8–16·9) | 13·7 (12·4–14·8) | 15·2 (13·8–16·6) Panama …

Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

BACKGROUND: Measurement of changes in health across locations is useful to compare and contrast changing epidemiological patterns against health system performance and identify specific needs for resource allocation in research, policy development, and programme decision making. Using the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we drew from two widely used summary measures to monitor such changes in population health: disability-adjusted life-years (DALYs) and healthy life expectancy (HALE). We used these measures to track trends and benchmark progress compared with e

Nuclear-Cytoplasmic Axis in Cancer: From Protein Mislocalization to Anticancer Drug Resistance.

Nucleocytoplasmic transport (NCT) regulates the spatial distribution of proteins and RNA between the nucleus and cytoplasm. NCT dysregulation can mislocalize tumor suppressors, DNA-repair factors, transcription factors, and drug targets in cancer. In this review, we conceptualize NCT-dependent protein mislocalization as a spatial regulatory framework for anticancer drug resistance, rather than as a catalogue of transport components. We systematically discuss how nuclear pore complex (NPC) remodeling, transport-receptor imbalance, post-translational modification (PTM)-regulated cargo routing, s

Совпадение в полном тексте источника
… hematologic signal | Investigational second-generation SINE evidence | [ 154 ] NCT06399640 | R/R MDS and AML | Ph1 | Eltanexor + venetoclax | Recruiting; rational combination strategy under active evaluation | Hematologic malignancy | Ongoing early clinical combination trial | [ 156 ] NCT02702492 (PANAMA …

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy.

Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse events. Hence, there is an urgent need for the development of next-generation treatments that, alone or in combination, stop the undesired autoimmune response and contribute to the restoration of homeostasis. This review analyzes current MS treatmen

Совпадение в полном тексте источника
… . | 150 × 10 6 cells | Single | Unreported | Unpublished aASVF | 2014–2018 | USA | II | NCT02157064 | Open-label | MS patients | 221 | Unreported | Unreported | Unreported | Unreported | Unreported | Unpublished alloUCMSCs | 2014–2017 | Panama | I/II | NCT02034188 | Open-label | MS patients | 20 | 2– …

Tumor angiogenesis as a target for dietary cancer prevention.

Between 2000 and 2050, the number of new cancer patients diagnosed annually is expected to double, with an accompanying increase in treatment costs of more than $80 billion over just the next decade. Efficacious strategies for cancer prevention will therefore be vital for improving patients' quality of life and reducing healthcare costs. Judah Folkman first proposed antiangiogenesis as a strategy for preventing dormant microtumors from progressing to invasive cancer. Although antiangiogenic drugs are now available for many advanced malignancies (colorectal, lung, breast, kidney, liver, brain,

Совпадение в полном тексте источника
… Notably, the Kuna Indians living on the San Blas Island of Panama—who have a ten-fold higher dietary intake of cacao compared to Panamanian mainlanders—have lower blood pressure, live longer, and have lower incidence of cancer compared to mainlanders [ 242 ]. …

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) are publishing a new edition of the ESMO/ASCO Global Curriculum (GC) thanks to contribution of 64 ESMO-appointed and 32 ASCO-appointed authors. First published in 2004 and updated in 2010, the GC edition 2016 answers to the need for updated recommendations for the training of physicians in medical oncology by defining the standard to be fulfilled to qualify as medical oncologists. At times of internationalisation of healthcare and increased mobility of patients and physicians, the GC aims to p

Совпадение в полном тексте источника
… of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland Michael Kosty, MD, FACP, FASCO Director, Scripps Green Cancer Center, Division of Hematology/Oncology, Scripps Clinic, La Jolla, California, USA Roberto Ivan Lopez, MD Centro Oncologico Punta Pacifica, Medical Oncology, Panama … , Panama Jean-Pierre Lotz, MD, Professor Head of the Department of Medical Oncology and Cellular Therapy, Medical Oncology Department, Tenon Assistance Publique—Hôpitaux de Paris, Paris, France Pia Österlund, MD, PhD, Docent Department of Oncology, HUCH Helsinki University Central Hospital, Helsinki …

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

BACKGROUND: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 comparative risk assessment (CRA) is a comprehensive approach to risk factor quantification that offers a useful tool for synthesising evidence on risks and risk-outcome associations. With each annual GBD study, we update the GBD CRA to incorporate improved methods, new risks and risk-outcome pairs, and new data on risk exposure levels and risk-outcome associations. METHODS: We used the CRA framework developed for previous iterations of GBD to estimate levels and trends in exposure, attributable deaths, and

Demographic, epidemiological, and health transitions: are they relevant to population health patterns in Africa?

BackgroundStudies of trends in population changes and epidemiological profiles in the developing world have overwhelmingly relied upon the concepts of demographic, epidemiological, and health transitions, even though their usefulness in describing and understanding population and health trends in developing countries has been repeatedly called into question. The issue is particularly relevant for the study of population health patterns in Africa and sub-Saharan Africa, as the history and experience there differs substantially from that of Western Europe and North America, for which these conce

Совпадение в полном тексте источника
… Countries in the upper non-western intermediate transition model include Indonesia, Colombia, Mexico, Brazil, Panama, Venezuela, Tunisia, Lebanon, and Thailand. …

Е-постеры.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Arizt De Leon 1 , Nathalie Ruíz 2 , Ricardo Mosquera 3 , Alaa Azmi Ahmad 4,5 , Ponce Science Health University 6 , and Norman Ramirez Lluch 7 1 Orthopaedic and Trauma, Hospital del Niño Dr José Renán Esquivel, Panamá, Panama 2 Orthopaedic and Trauma, Hospital Santo Tomás, Panamá, Panama 3 Orthopaedic … and Trauma, Hospital de Especialidades Pediátricas Omar Torrijos Herrera, Panamá, Panama 4 Orthopaedic Surgery, Palestine Polytechnic University, Palestine 5 University of Toledo, Ohio, USA 6 Ponce Science Health University, Puerto Rico 7 Mayaguez Medical Center, Puerto Rico, Puerto Rico Introduction …

Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.

BACKGROUND: Cervical cancer is the fourth most common cause of cancer-related death amongst females worldwide. Persistent infection with high-risk human papillomavirus (HPV) is the key factor in cervical cancer development. HPV vaccines aim to prevent cancer by generating antibodies against HPV infection. OBJECTIVES: To evaluate the safety and efficacy of HPV vaccines, in females and males, to prevent cervical cancer and other HPV-related diseases, in standard (pairwise) and network meta-analysis (NMA) of randomised controlled trials. SEARCH METHODS: On 10 January 2022, we searched the Cochr

10th Trends in Medical Mycology Held on 8 to 11 October 2021, Aberdeen, Scotland, Organized by the European Confederation of Medical Mycology (ECMM).

Plenary Sessions: [...].

Премии победителей и резюме 32nd Ежегодный симпозиум Общества протеинов; Бостон, ОЭТ, июль 9-12, 2018.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.